PCA analysis for Study ST001237

(Analysis AN002055 )

Select 2 or more experimental factors for PCA analysis.
GroupCombined factors (this analysis)
Time point:baseline | OS_Censor (1 means the time is a censoring time and 0 means a failure time in OS):1 | CRF_MSKCC_Risk_Group:FAVORABLE | Treatment:EVEROLIMUS | Prior antiangiogenic regimens (≥2):FALSE
Time point:baseline | OS_Censor (1 means the time is a censoring time and 0 means a failure time in OS):1 | CRF_MSKCC_Risk_Group:FAVORABLE | Treatment:EVEROLIMUS | Prior antiangiogenic regimens (≥2):TRUE
Time point:baseline | OS_Censor (1 means the time is a censoring time and 0 means a failure time in OS):1 | CRF_MSKCC_Risk_Group:FAVORABLE | Treatment:NIVOLUMAB | Prior antiangiogenic regimens (≥2):FALSE
Time point:baseline | OS_Censor (1 means the time is a censoring time and 0 means a failure time in OS):1 | CRF_MSKCC_Risk_Group:FAVORABLE | Treatment:NIVOLUMAB | Prior antiangiogenic regimens (≥2):TRUE
Time point:baseline | OS_Censor (1 means the time is a censoring time and 0 means a failure time in OS):1 | CRF_MSKCC_Risk_Group:INTERMEDIATE | Treatment:EVEROLIMUS | Prior antiangiogenic regimens (≥2):FALSE
Time point:baseline | OS_Censor (1 means the time is a censoring time and 0 means a failure time in OS):1 | CRF_MSKCC_Risk_Group:INTERMEDIATE | Treatment:EVEROLIMUS | Prior antiangiogenic regimens (≥2):TRUE
Time point:baseline | OS_Censor (1 means the time is a censoring time and 0 means a failure time in OS):1 | CRF_MSKCC_Risk_Group:INTERMEDIATE | Treatment:NIVOLUMAB | Prior antiangiogenic regimens (≥2):FALSE
Time point:baseline | OS_Censor (1 means the time is a censoring time and 0 means a failure time in OS):1 | CRF_MSKCC_Risk_Group:INTERMEDIATE | Treatment:NIVOLUMAB | Prior antiangiogenic regimens (≥2):TRUE
Time point:baseline | OS_Censor (1 means the time is a censoring time and 0 means a failure time in OS):1 | CRF_MSKCC_Risk_Group:POOR | Treatment:EVEROLIMUS | Prior antiangiogenic regimens (≥2):FALSE
Time point:baseline | OS_Censor (1 means the time is a censoring time and 0 means a failure time in OS):1 | CRF_MSKCC_Risk_Group:POOR | Treatment:EVEROLIMUS | Prior antiangiogenic regimens (≥2):TRUE
Time point:baseline | OS_Censor (1 means the time is a censoring time and 0 means a failure time in OS):1 | CRF_MSKCC_Risk_Group:POOR | Treatment:NIVOLUMAB | Prior antiangiogenic regimens (≥2):FALSE
Time point:baseline | OS_Censor (1 means the time is a censoring time and 0 means a failure time in OS):1 | CRF_MSKCC_Risk_Group:POOR | Treatment:NIVOLUMAB | Prior antiangiogenic regimens (≥2):TRUE
Time point:baseline | OS_Censor (1 means the time is a censoring time and 0 means a failure time in OS):- | CRF_MSKCC_Risk_Group:FAVORABLE | Treatment:EVEROLIMUS | Prior antiangiogenic regimens (≥2):FALSE
Time point:baseline | OS_Censor (1 means the time is a censoring time and 0 means a failure time in OS):- | CRF_MSKCC_Risk_Group:FAVORABLE | Treatment:EVEROLIMUS | Prior antiangiogenic regimens (≥2):TRUE
Time point:baseline | OS_Censor (1 means the time is a censoring time and 0 means a failure time in OS):- | CRF_MSKCC_Risk_Group:FAVORABLE | Treatment:NIVOLUMAB | Prior antiangiogenic regimens (≥2):FALSE
Time point:baseline | OS_Censor (1 means the time is a censoring time and 0 means a failure time in OS):- | CRF_MSKCC_Risk_Group:FAVORABLE | Treatment:NIVOLUMAB | Prior antiangiogenic regimens (≥2):TRUE
Time point:baseline | OS_Censor (1 means the time is a censoring time and 0 means a failure time in OS):- | CRF_MSKCC_Risk_Group:INTERMEDIATE | Treatment:EVEROLIMUS | Prior antiangiogenic regimens (≥2):FALSE
Time point:baseline | OS_Censor (1 means the time is a censoring time and 0 means a failure time in OS):- | CRF_MSKCC_Risk_Group:INTERMEDIATE | Treatment:EVEROLIMUS | Prior antiangiogenic regimens (≥2):TRUE
Time point:baseline | OS_Censor (1 means the time is a censoring time and 0 means a failure time in OS):- | CRF_MSKCC_Risk_Group:INTERMEDIATE | Treatment:NIVOLUMAB | Prior antiangiogenic regimens (≥2):FALSE
Time point:baseline | OS_Censor (1 means the time is a censoring time and 0 means a failure time in OS):- | CRF_MSKCC_Risk_Group:INTERMEDIATE | Treatment:NIVOLUMAB | Prior antiangiogenic regimens (≥2):TRUE
Time point:baseline | OS_Censor (1 means the time is a censoring time and 0 means a failure time in OS):- | CRF_MSKCC_Risk_Group:POOR | Treatment:EVEROLIMUS | Prior antiangiogenic regimens (≥2):FALSE
Time point:baseline | OS_Censor (1 means the time is a censoring time and 0 means a failure time in OS):- | CRF_MSKCC_Risk_Group:POOR | Treatment:EVEROLIMUS | Prior antiangiogenic regimens (≥2):TRUE
Time point:baseline | OS_Censor (1 means the time is a censoring time and 0 means a failure time in OS):- | CRF_MSKCC_Risk_Group:POOR | Treatment:NIVOLUMAB | Prior antiangiogenic regimens (≥2):FALSE
Time point:baseline | OS_Censor (1 means the time is a censoring time and 0 means a failure time in OS):- | CRF_MSKCC_Risk_Group:POOR | Treatment:NIVOLUMAB | Prior antiangiogenic regimens (≥2):TRUE
Time point:week 4 | OS_Censor (1 means the time is a censoring time and 0 means a failure time in OS):1 | CRF_MSKCC_Risk_Group:FAVORABLE | Treatment:EVEROLIMUS | Prior antiangiogenic regimens (≥2):FALSE
Time point:week 4 | OS_Censor (1 means the time is a censoring time and 0 means a failure time in OS):1 | CRF_MSKCC_Risk_Group:FAVORABLE | Treatment:EVEROLIMUS | Prior antiangiogenic regimens (≥2):TRUE
Time point:week 4 | OS_Censor (1 means the time is a censoring time and 0 means a failure time in OS):1 | CRF_MSKCC_Risk_Group:FAVORABLE | Treatment:NIVOLUMAB | Prior antiangiogenic regimens (≥2):FALSE
Time point:week 4 | OS_Censor (1 means the time is a censoring time and 0 means a failure time in OS):1 | CRF_MSKCC_Risk_Group:FAVORABLE | Treatment:NIVOLUMAB | Prior antiangiogenic regimens (≥2):TRUE
Time point:week 4 | OS_Censor (1 means the time is a censoring time and 0 means a failure time in OS):1 | CRF_MSKCC_Risk_Group:INTERMEDIATE | Treatment:EVEROLIMUS | Prior antiangiogenic regimens (≥2):FALSE
Time point:week 4 | OS_Censor (1 means the time is a censoring time and 0 means a failure time in OS):1 | CRF_MSKCC_Risk_Group:INTERMEDIATE | Treatment:EVEROLIMUS | Prior antiangiogenic regimens (≥2):TRUE
Time point:week 4 | OS_Censor (1 means the time is a censoring time and 0 means a failure time in OS):1 | CRF_MSKCC_Risk_Group:INTERMEDIATE | Treatment:NIVOLUMAB | Prior antiangiogenic regimens (≥2):FALSE
Time point:week 4 | OS_Censor (1 means the time is a censoring time and 0 means a failure time in OS):1 | CRF_MSKCC_Risk_Group:INTERMEDIATE | Treatment:NIVOLUMAB | Prior antiangiogenic regimens (≥2):TRUE
Time point:week 4 | OS_Censor (1 means the time is a censoring time and 0 means a failure time in OS):1 | CRF_MSKCC_Risk_Group:POOR | Treatment:EVEROLIMUS | Prior antiangiogenic regimens (≥2):FALSE
Time point:week 4 | OS_Censor (1 means the time is a censoring time and 0 means a failure time in OS):1 | CRF_MSKCC_Risk_Group:POOR | Treatment:NIVOLUMAB | Prior antiangiogenic regimens (≥2):FALSE
Time point:week 4 | OS_Censor (1 means the time is a censoring time and 0 means a failure time in OS):1 | CRF_MSKCC_Risk_Group:POOR | Treatment:NIVOLUMAB | Prior antiangiogenic regimens (≥2):TRUE
Time point:week 4 | OS_Censor (1 means the time is a censoring time and 0 means a failure time in OS):- | CRF_MSKCC_Risk_Group:FAVORABLE | Treatment:EVEROLIMUS | Prior antiangiogenic regimens (≥2):FALSE
Time point:week 4 | OS_Censor (1 means the time is a censoring time and 0 means a failure time in OS):- | CRF_MSKCC_Risk_Group:FAVORABLE | Treatment:EVEROLIMUS | Prior antiangiogenic regimens (≥2):TRUE
Time point:week 4 | OS_Censor (1 means the time is a censoring time and 0 means a failure time in OS):- | CRF_MSKCC_Risk_Group:FAVORABLE | Treatment:NIVOLUMAB | Prior antiangiogenic regimens (≥2):FALSE
Time point:week 4 | OS_Censor (1 means the time is a censoring time and 0 means a failure time in OS):- | CRF_MSKCC_Risk_Group:FAVORABLE | Treatment:NIVOLUMAB | Prior antiangiogenic regimens (≥2):TRUE
Time point:week 4 | OS_Censor (1 means the time is a censoring time and 0 means a failure time in OS):- | CRF_MSKCC_Risk_Group:INTERMEDIATE | Treatment:EVEROLIMUS | Prior antiangiogenic regimens (≥2):FALSE
Time point:week 4 | OS_Censor (1 means the time is a censoring time and 0 means a failure time in OS):- | CRF_MSKCC_Risk_Group:INTERMEDIATE | Treatment:EVEROLIMUS | Prior antiangiogenic regimens (≥2):TRUE
Time point:week 4 | OS_Censor (1 means the time is a censoring time and 0 means a failure time in OS):- | CRF_MSKCC_Risk_Group:INTERMEDIATE | Treatment:NIVOLUMAB | Prior antiangiogenic regimens (≥2):FALSE
Time point:week 4 | OS_Censor (1 means the time is a censoring time and 0 means a failure time in OS):- | CRF_MSKCC_Risk_Group:INTERMEDIATE | Treatment:NIVOLUMAB | Prior antiangiogenic regimens (≥2):TRUE
Time point:week 4 | OS_Censor (1 means the time is a censoring time and 0 means a failure time in OS):- | CRF_MSKCC_Risk_Group:POOR | Treatment:EVEROLIMUS | Prior antiangiogenic regimens (≥2):FALSE
Time point:week 4 | OS_Censor (1 means the time is a censoring time and 0 means a failure time in OS):- | CRF_MSKCC_Risk_Group:POOR | Treatment:EVEROLIMUS | Prior antiangiogenic regimens (≥2):TRUE
Time point:week 4 | OS_Censor (1 means the time is a censoring time and 0 means a failure time in OS):- | CRF_MSKCC_Risk_Group:POOR | Treatment:NIVOLUMAB | Prior antiangiogenic regimens (≥2):FALSE
Time point:week 4 | OS_Censor (1 means the time is a censoring time and 0 means a failure time in OS):- | CRF_MSKCC_Risk_Group:POOR | Treatment:NIVOLUMAB | Prior antiangiogenic regimens (≥2):TRUE
Time point:week 8 | OS_Censor (1 means the time is a censoring time and 0 means a failure time in OS):1 | CRF_MSKCC_Risk_Group:FAVORABLE | Treatment:NIVOLUMAB | Prior antiangiogenic regimens (≥2):FALSE
Time point:week 8 | OS_Censor (1 means the time is a censoring time and 0 means a failure time in OS):1 | CRF_MSKCC_Risk_Group:FAVORABLE | Treatment:NIVOLUMAB | Prior antiangiogenic regimens (≥2):TRUE
Time point:week 8 | OS_Censor (1 means the time is a censoring time and 0 means a failure time in OS):1 | CRF_MSKCC_Risk_Group:INTERMEDIATE | Treatment:NIVOLUMAB | Prior antiangiogenic regimens (≥2):FALSE
Time point:week 8 | OS_Censor (1 means the time is a censoring time and 0 means a failure time in OS):1 | CRF_MSKCC_Risk_Group:INTERMEDIATE | Treatment:NIVOLUMAB | Prior antiangiogenic regimens (≥2):TRUE
Time point:week 8 | OS_Censor (1 means the time is a censoring time and 0 means a failure time in OS):1 | CRF_MSKCC_Risk_Group:POOR | Treatment:NIVOLUMAB | Prior antiangiogenic regimens (≥2):FALSE
Time point:week 8 | OS_Censor (1 means the time is a censoring time and 0 means a failure time in OS):1 | CRF_MSKCC_Risk_Group:POOR | Treatment:NIVOLUMAB | Prior antiangiogenic regimens (≥2):TRUE
Time point:week 8 | OS_Censor (1 means the time is a censoring time and 0 means a failure time in OS):- | CRF_MSKCC_Risk_Group:FAVORABLE | Treatment:NIVOLUMAB | Prior antiangiogenic regimens (≥2):FALSE
Time point:week 8 | OS_Censor (1 means the time is a censoring time and 0 means a failure time in OS):- | CRF_MSKCC_Risk_Group:FAVORABLE | Treatment:NIVOLUMAB | Prior antiangiogenic regimens (≥2):TRUE
Time point:week 8 | OS_Censor (1 means the time is a censoring time and 0 means a failure time in OS):- | CRF_MSKCC_Risk_Group:INTERMEDIATE | Treatment:NIVOLUMAB | Prior antiangiogenic regimens (≥2):FALSE
Time point:week 8 | OS_Censor (1 means the time is a censoring time and 0 means a failure time in OS):- | CRF_MSKCC_Risk_Group:INTERMEDIATE | Treatment:NIVOLUMAB | Prior antiangiogenic regimens (≥2):TRUE
Time point:week 8 | OS_Censor (1 means the time is a censoring time and 0 means a failure time in OS):- | CRF_MSKCC_Risk_Group:POOR | Treatment:NIVOLUMAB | Prior antiangiogenic regimens (≥2):FALSE
Time point:week 8 | OS_Censor (1 means the time is a censoring time and 0 means a failure time in OS):- | CRF_MSKCC_Risk_Group:POOR | Treatment:NIVOLUMAB | Prior antiangiogenic regimens (≥2):TRUE

OR

Perform PCA on individual factors (all analyses in study)
  logo